Genentech's Pertuzumab Shows 6-Month PFS Gain
Findings from Genentech Inc.'s randomized Phase III CLEOPATRA study of pertuzumab in HER2-positive metastatic breast cancer suggested the drug, in combination with Herceptin (trastuzumab) and docetaxel chemotherapy, provided a 38 percent improvement in progression-free survival (PFS) compared to Herceptin and docetaxel alone in previously untreated HER2-positive metastatic breast cancer (mBC).
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter